A blood-based biomarker of body-wide inflammation called a low systemic immune-inflammation index (SII) before a standard Kasai surgical procedure…
Articles by Steve Bryson, PhD
Six months of Calliditas Therapeutics‘ investigational therapy setanaxib safely and significantly reduced signs of liver damage in people with…
Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of…
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for…
Children with biliary atresia show developmental problems, including language delays, following a living donor liver transplant (LDLT) in infancy…
A living donor liver transplant successfully managed liver failure in a 6-month-old boy with progressive familial intrahepatic cholestasis type 8…
Clinical genome sequencing, or cGS, testing to detect a rare genetic disease such as Alagille syndrome, resulted in a…
A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people…
One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most…